Table 4.
Meta‐Analysis Results for 11.25 MET h/week Increase on CVD and T2DM: Sensitivity to Transformation Assumptions
| Health Outcome (ICD‐10 Code) | RR for 11.25 MET h/week Increase in PA, With 95% CIs | |||||
|---|---|---|---|---|---|---|
| 0.25 Power | 0.375 Power | 0.5 Power | 0.75 Power | Linear | Log Linear | |
| CVD incidence (I00–I99) | 0.83 (0.77, 0.89) | 0.85 (0.79, 0.91) | 0.86 (0.80, 0.92) | 0.89 (0.83, 0.96) | 0.92 (0.86, 0.98) | 0.91 (0.85, 0.97) |
| CVD mortality (I00–I99) | 0.77 (0.71, 0.84) | 0.78 (0.70, 0.87) | 0.79 (0.70, 0.90) | 0.80 (0.67, 0.95) | 0.80 (0.63, 1.01) | 0.82 (0.70, 0.95) |
| Stroke incidence (I60–I69) | 0.82 (0.77, 0.87) | 0.82 (0.77, 0.87) | 0.82 (0.77, 0.88) | 0.84 (0.77, 0.91) | 0.85 (0.77, 0.94) | 0.85 (0.77, 0.93) |
| CHD incidence (I20–I25) | 0.80 (0.75, 0.86) | 0.82 (0.77, 0.88) | 0.84 (0.79, 0.90) | 0.88 (0.82, 0.93) | 0.90 (0.85, 0.96) | 0.89 (0.84, 0.95) |
| CHD mortality (I20–25) | 0.80 (0.58, 1.09) | 0.81 (0.61, 1.08) | 0.82 (0.63, 1.07) | 0.84 (0.67, 1.05) | 0.86 (0.70, 1.05) | 0.85 (0.68, 1.06) |
| Heart failure incidence (I50) | 0.81 (0.76, 0.86) | 0.83 (0.79, 0.89) | 0.86 (0.81, 0.91) | 0.89 (0.84, 0.95) | 0.92 (0.87, 0.98) | 0.91 (0.86, 0.97) |
| MI incidence (I21–22) | 0.75 (0.62, 0.89) | 0.76 (0.63, 0.91) | 0.77 (0.65, 0.93) | 0.81 (0.67, 0.97) | 0.84 (0.70, 1.00) | 0.83 (0.69, 0.99) |
| T2DM incidence (E11) | 0.74 (0.72, 0.77) | 0.73 (0.71, 0.76) | 0.72 (0.70, 0.75) | 0.70 (0.68, 0.72) | 0.68 (0.66, 0.70) | 0.69 (0.67, 0.71) |
CHD indicates coronary heart disease; CVD, cardiovascular disease; ICD, International Classification of Disease; MET, metabolic equivalent of task; MI, myocardial infarction; PA, physical activity; RR, relative risk; T2DM, type 2 diabetes mellitus.